Federal Register / Vol. 87, No. 56 / Wednesday, March 23, 2022 / Notices 16497 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on February 28, 2022, 

Johnson Matthey Pharmaceutical 

Materials, Inc., 2003 Nolte Drive, West 

Deptford, New Jersey 08066–1742, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

Marihuana ....................... 7360 I 

Tetrahydrocannabinols ... 7370 I 

Noroxymorphone ............ 9145 I 

Difenoxin ......................... 9168 I 

Amphetamine ................. 1100 II 

Methamphetamine .......... 1105 II 

Lisdexamfetamine .......... 1205 II 

Methylphenidate ............. 1724 II 

Nabilone ......................... 7379 II 

ANPP (4-Anilino-Nphenethyl-4-piperidine).8333 II 

Norfentanyl (N-phenyl-N- 

(piperidin-4-yl) 

propionamide).

8366 II 

Cocaine .......................... 9041 II 

Codeine .......................... 9050 II 

Dihydrocodeine ............... 9120 II 

Oxycodone ..................... 9143 II 

Hydromorphone .............. 9150 II 

Diphenoxylate ................. 9170 II 

Ecgonine ......................... 9180 II 

Hydrocodone .................. 9193 II 

Levorphanol .................... 9220 II 

Meperidine ...................... 9230 II 

Methadone ...................... 9250 II 

Methadone intermediate 9254 II 

Morphine ......................... 9300 II 

Thebaine ......................... 9333 II 

Opium tincture ................ 9630 II 

Oxymorphone ................. 9652 II 

Noroxymorphone ............ 9668 II 

Alfentanil ......................... 9737 II 

Remifentanil .................... 9739 II 

Sufentanil ........................ 9740 II 

Tapentadol ...................... 9780 II 

Fentanyl .......................... 9801 II 

The company plans to bulk 

manufacture the listed controlled 

substances for the internal use 

intermediates or for sale to its 

customers. In reference to drug codes 

7360 (Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. No other activities for these 

drug codes are authorized for this 

registration. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–06159 Filed 3–22–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–979] 

Importer of Controlled Substances 

Application: Sharp Clinical Services, 

Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Sharp Clinical Services, Inc. 

has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before April 22, 2022. Such 

persons may also file a written request 

for a hearing on the application on or 

before April 22, 2022. 

ADDRESSES: The DEA requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on February 2, 2022, Sharp 

Clinical Services, Inc. 2400 Baglyos 

Circle, Bethlehem, Pennsylvania 18020– 

8024, applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

3,4- 

Methylenedioxymethamphetamine.

7405 I 

The company plans to import the 

listed control substances for clinical 

trials. No other activity for these drug 

codes is authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–06161 Filed 3–22–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–984] 

Bulk Manufacturer of Controlled 

Substances Application: Siemens 

Healthcare Diagnostics, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Siemens Healthcare 

Diagnostics, Inc. has applied to be 

registered as a bulk manufacturer of 

basic class(es) of controlled 

substance(s). Refer to Supplementary 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before May 23, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

May 23, 2022. 

ADDRESSES: The Drug Enforcement 

Administration (DEA) requires that all 

comments be submitted electronically 


jspears on DSK121TN23PROD with NOTICES1